Realeve

Executive Summary

Realeve is a Cleveland-based medical device company developing the Pulsante™ implant, a battery-free, wireless sphenopalatine ganglion (SPG) microstimulation system. The device is designed to be minimally invasively implanted and activated by a handheld controller, offering a novel neuromodulation approach for headache disorders such as cluster headache and migraine. Unlike traditional implanted stimulators, the battery-free design reduces device bulk and eliminates replacement surgeries, potentially lowering complications and cost. Realeve's technology was founded in 2019 and is still in early stages, with no disclosed funding, revenue, or regulatory milestones. The company operates in the competitive neuromodulation space against established players like electroCore (gammaCore) and implantable devices from Medtronic. Key risks include regulatory hurdles, clinical validation, and adoption by physicians. However, the wireless, battery-free form factor could differentiate it if safety and efficacy are demonstrated in clinical trials.

Upcoming Catalysts (preview)

• Q4 2026Early feasibility clinical trial results40% success
• Q2 2027FDA breakthrough device designation or initial funding30% success
• Q3 2027Strategic partnership with a larger neuromodulation company20% success